The clearance allows FebriDx to be marketed in the US for use by healthcare professionals as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in patients presenting in urgent care or emergency care settings. FebriDx is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection
- Forums
- ASX - By Stock
- LDX
- Ann: Lumos Receives US FDA Clearance for FebriDx
Ann: Lumos Receives US FDA Clearance for FebriDx, page-45
-
- There are more pages in this discussion • 376 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LDX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.2¢ |
Change
-0.002(4.55%) |
Mkt cap ! $20.21M |
Open | High | Low | Value | Volume |
4.3¢ | 4.3¢ | 4.0¢ | $39.55K | 966.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 236607 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.042 |
4 | 345418 | 0.040 |
1 | 25000 | 0.039 |
3 | 535000 | 0.038 |
1 | 100000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 236607 | 3 |
0.045 | 138530 | 2 |
0.046 | 600000 | 2 |
0.048 | 218015 | 3 |
0.049 | 200000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
LDX (ASX) Chart |